Early CD49d downmodulation in chronic lymphocytic leukemia patients treated front-line with ibrutinib plus rituximab predicts long-term response.
Nadia PeragineMaria Stefania De ProprisStefania IntoppaMaria Laura MilaniFrancesca Romana MauroAntonio CuneoGian Matteo RigolinIlaria Del GiudiceRobin FoàAnna GuariniPublished in: Leukemia & lymphoma (2022)